JMP Securities Starts NovoCure Ltd. (NVCR) at Market Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
JPMorgan Starts NovoCure Ltd. (NVCR) at Overweight
October 27, 2015 8:11 AM EDTJPMorgan initiated coverage on NovoCure Ltd. (NASDAQ: NVCR) with an Overweight rating and a price target of $29.00.
For an analyst ratings summary and ratings history on NovoCure Ltd. click here. For more ratings news on NovoCure Ltd. click here.
Shares of NovoCure Ltd. closed at $20.58 yesterday.
... MoreWedbush Starts NovoCure Ltd. (NVCR) at Outperform
October 27, 2015 7:28 AM EDTWedbush initiates coverage on NovoCure Ltd. (NASDAQ: NVCR) with a Outperform rating and a price target of $30.00.
Analyst Tao Levy commented, " NovoCure is a rapidly emerging, commercial stage company whose flagship Tumor Treating Fields (TTFields) technology reverses tumor growth by disrupting cell... More
Novocure (NVCR) Reports Q3 Loss of $2.09/Share
October 26, 2015 4:14 PM EDTNovocure (NASDAQ: NVCR) reported Q3 EPS of ($2.09), versus ($1.45) reported last year. Revenue for the quarter came in at $8.95 million, versus $4.37 million reported last year.
Third Quarter 2015 Operating Statistics
354 prescriptions were received in the quarter, an... More